Stock ARWR ARROWHEAD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Real-time Estimate Cboe BZX
Other stock markets
 01:56:36 2024-04-29 pm EDT 		5-day change 1st Jan Change
23.39 USD +5.74% Intraday chart for Arrowhead Pharmaceuticals, Inc. -1.96% -23.37%
Apr. 24 Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease CI
Apr. 07 Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
BU
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
BU
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
BU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
BU
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
BU
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BU
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
BU
Arrowhead Pharmaceuticals : 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference View Presentation
PU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
BU
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
BU
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
BU
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
BU
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
BU
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
BU
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BU
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
BU
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
BU
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
BU
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARWR Stock
  4. News Arrowhead Pharmaceuticals, Inc.
  5. Press Releases